<code id='7B3ABFF37F'></code><style id='7B3ABFF37F'></style>
    • <acronym id='7B3ABFF37F'></acronym>
      <center id='7B3ABFF37F'><center id='7B3ABFF37F'><tfoot id='7B3ABFF37F'></tfoot></center><abbr id='7B3ABFF37F'><dir id='7B3ABFF37F'><tfoot id='7B3ABFF37F'></tfoot><noframes id='7B3ABFF37F'>

    • <optgroup id='7B3ABFF37F'><strike id='7B3ABFF37F'><sup id='7B3ABFF37F'></sup></strike><code id='7B3ABFF37F'></code></optgroup>
        1. <b id='7B3ABFF37F'><label id='7B3ABFF37F'><select id='7B3ABFF37F'><dt id='7B3ABFF37F'><span id='7B3ABFF37F'></span></dt></select></label></b><u id='7B3ABFF37F'></u>
          <i id='7B3ABFF37F'><strike id='7B3ABFF37F'><tt id='7B3ABFF37F'><pre id='7B3ABFF37F'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:explore    Page View:89223
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In